Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis

References

• Vina ER, Kwoh CK. Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol. 2018;30(2):160–167.
   Google Scholar
• Kassebaum NJ, Arora M, Barber RM. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1603–1658.
   Google Scholar
• Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheumatism. 2012;64(6):1697–1707.
   Google Scholar
• Jones IA, Togashi R, Wilson ML, et al. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019 Feb;15(2):77–90.
   Google Scholar
• Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3;27:1578–1589.
   Google Scholar
• Centre NCG. National institute for health and clinical excellence: guidance. Osteoarthritis: care and management in adults. London: National Institute for Health and Care Excellence (UK); 2014.
   Google Scholar
• Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019 Feb;25(2):Cd013273.
   Google Scholar
• da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017 Jul 8;390(10090):e21–e33.
   Google Scholar
• Oo WM, Yu SP, Daniel MS, et al. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs. 2018 Dec;23(4):331–347.
   Google Scholar
• Nguyen C, Rannou F. The safety of intra-articular injections for the treatment of knee osteoarthritis: a critical narrative review. Expert Opin Drug Saf. 2017 Aug;16(8):897–902.
   Google Scholar
• Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):135–140.
   Google Scholar
• Fan J, de Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87(1):93–120.
   Google Scholar
• Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995 Mar-Apr;23(2):115–123.
   Google Scholar
• Derendorf H, Mollmann H, Gruner A, et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986 Mar;39(3):313–317.
   Google Scholar
• Kraus VB, Conaghan PG, Aazami HA, et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis Cartilage. 2018 Jan;26(1):34–42.
   Google Scholar
• Caldwell JR. Intra-articular corticosteroids. Guide to selection and indications for use. Drugs. 1996 Oct;52(4):507–514.
   Google Scholar
• Goa KL, Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs. 1994 Mar;47(3):536–566.
   Google Scholar
• Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 Oct;25(10):1598–1606.
   Google Scholar
• Chernchujit B, Tharakulphan S, Apivatgaroon A, et al. Accuracy comparisons of intra-articular knee injection between the new modified anterolateral Approach and superolateral approach in patients with symptomatic knee osteoarthritis without effusion. Asia Pac J Sports Med Arthrosc Rehabil Technol. 2019;17:1–4.
   Google Scholar
• Douglas RJ. Aspiration and injection of the knee joint: approach portal. Knee Surg Relat Res. 2014 Mar;26(1):1–6.
   Google Scholar
• Maricar N, Parkes MJ, Callaghan MJ, et al. Where and how to inject the knee–a systematic review. Semin Arthritis Rheum. 2013 Oct;43(2):195–203.
   Google Scholar
• Curtiss HM, Finnoff JT, Peck E, et al. Accuracy of ultrasound-guided and palpation-guided knee injections by an experienced and less-experienced injector using a superolateral approach: a cadaveric study. PM&R. 2011 June 01;3(6):507–515.
   Google Scholar
• Berkoff DJ, Miller LE, Block JE. Clinical utility of ultrasound guidance for intra-articular knee injections: a review. Clin Interv Aging. 2012;7:89–95.
   Google Scholar
• Sakellariou G, Conaghan PG, Zhang W, et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017;76(9):1484–1494.
   Google Scholar
• Koutsianas C, Klocke R. Efficacy of ultrasound-guided versus landmark-guided injections in rheumatology: a systematic review. Rheumatology (Oxford). 2017;56(suppl_2). Available from: https://academic.oup.com/rheumatology/article/56/suppl_2/kex062.267/4106769
   Google Scholar
• Daniels EW, Cole D, Jacobs B, et al. Existing Evidence on Ultrasound-Guided Injections in Sports Medicine. Orthop J Sports Med. 2018;6(2):2325967118756576.
   Google Scholar
• Oo WM, Bo MT. Role of ultrasonography in knee osteoarthritis. J Clin Rheumatol. 2016 Sep;22(6):324–329.
   Google Scholar
• Wind WM Jr., Smolinski RJ. Reliability of common knee injection sites with low-volume injections. J Arthroplasty. 2004 Oct;19(7):858–861.
   Google Scholar
• Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med. 2015;372(11):1040–1047.
   Google Scholar
• Petersen SK, Hansen I, Andreasen RA. Low frequency of septic arthritis after arthrocentesis and intra-articular glucocorticoid injection. Scand J Rheumatol. 2019 May;31:1–5.
   Google Scholar
• Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician. 2002 July;15(66(2)):283–289.
   Google Scholar
• Scherer J, Rainsford KD, Kean CA, et al. Pharmacology of intra-articular triamcinolone. Inflammopharmacology. 2014 Aug;22(4):201–217.
   Google Scholar
• Gotte AC. Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature. Open Access Rheumatol. 2009;1:37–49.
   Google Scholar
• de Jong BA, Dahmen R, Hogeweg JA, et al. Intra-articular triamcinolone acetonide injection in patients with capsulitis of the shoulder: a comparative study of two dose regimens. Clin Rehabil. 1998 Jun;12(3):211–215.
   Google Scholar
• Charlesworth J, Fitzpatrick J, Perera NKP, et al. Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee. BMC Musculoskelet Disord. 2019 Apr 09;20(1):151.
   Google Scholar
• Buyuk AF, Kilinc E, Camurcu IY, et al. Compared Efficacy of Intra-articular Injection of Methylprednisolone and Triamcinolone. Acta Ortop Bras. 2017 Sep-Oct;25(5):206–208.
   Google Scholar
• Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996 Sep;23(9):1579–1585.
   Google Scholar
• Chen AL, Desai P, Adler EM, et al. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am Vol. 2002 Jul;84(7):1142–1147.
   Google Scholar
• Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res. 2004 Feb;(419):130–137.
   Google Scholar
• Bowman S, Awad ME, Hamrick MW, et al. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018 Feb 16;7(1):6.
   Google Scholar
• Rang HP. The receptor concept: pharmacology’s big idea. Br J Pharmacol. 2006 Jan;147(Suppl 1):S9–16.
   Google Scholar
• Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. Aaps J. 2008 Dec;10(4):537–551.
   Google Scholar
• Zito MMPM. Pharmacodynamics. Treasure Island (FL): StatPearls Publishing; 2019. ( (StatPearls)).
   Google Scholar
• Bauer LA. Clinical pharmacokinetics and pharmacodynamics. In: DiPiro JT, Talbert RL, Yee GC, editors. Pharmacotherapy: A pathophysiologic approach. New York, NY: McGraw-Hill Education; 2017. p. 10e.
   Google Scholar
• Hollander JL, Brown EM Jr., Jessar RA, et al. Hydrocortisone and cortisone injected into arthritic joints; comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc. 1951 Dec 22;147(17):1629–1635.
   Google Scholar
• Nixon M, Andrew R, Chapman KE. It takes two to tango: dimerisation of glucocorticoid receptor and its anti-inflammatory functions. Steroids. 2013 Jan;78(1):59–68.
   Google Scholar
• Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res. 2018;11:2189–2196.
   Google Scholar
• Jüni P, Hari R, Rutjes AWS, et al. Intra‐articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015 Oct 22;(10):CD005328.
   Google Scholar
• Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. Clin Rheumatol. 2014 Dec;33(12):1695–1706.
   Google Scholar
• van Middelkoop M, Arden NK, Atchia I, et al. The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. Osteoarthritis Cartilage. 2016 Jul;24(7):1143–1152.
   Google Scholar
• Matzkin EG, Curry EJ, Kong Q, et al. Efficacy and treatment response of intra-articular corticosteroid injections in patients with symptomatic knee osteoarthritis. J Am Acad Orthop Surg. 2017 Oct;25(10):703–714.
   Google Scholar
• Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular corticosteroids on articular cartilage: a systematic review. Orthop J Sports Med. 2015 May;3(5):2325967115581163.
   Google Scholar
• Wehling P, Evans C, Wehling J, et al. Effectiveness of intra-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskelet Dis. 2017 Aug;9(8):183–196.
   Google Scholar
• McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. Jama. 2017 May 16;317(19):1967–1975.
   Google Scholar
• Conduah AH, Baker CL, Baker CL. Managing joint pain in osteoarthritis: safety and efficacy of hylan G-F 20. J Pain Res. 2009 Jul 6;2:87–98.
   Google Scholar
• Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy [Review Article]. Nat Rev Rheumatol. 2013 Nov 05;10:11. online.
   Google Scholar
• Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54–67.
   Google Scholar
• Webb D, Naidoo P. Viscosupplementation for knee osteoarthritis: a focus on Hylan G-F 20. Orthop Res Rev. 2018;10:73–81.
   Google Scholar
• Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16(1):321.
   Google Scholar
• He W-W, Kuang M-J, Zhao J, et al. Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: A meta-analysis. Int J Surg. 2017 Mar 01;39:95–103.
   Google Scholar
• Rutjes AW, Juni P, da Costa BR, et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 7;157(3):180–191.
   Google Scholar
• Richette P, Chevalier X, Ea HK, et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open. 2015;1(1):e000071.
   Google Scholar
• Printz JO, Lee JJ, Knesek M, et al. Conflict of interest in the assessment of hyaluronic acid injections for osteoarthritis of the knee: an updated systematic review. J Arthroplasty. 2013 Sep;28(8 Suppl):30–33.e1.
   Google Scholar
• Sanders JO, Murray J, Gross L. Non-arthroplasty treatment of osteoarthritis of the knee. J Am Acad Orthop Surg. 2014 Apr;22(4):256–260.
   Google Scholar
• Honvo G, Reginster J-Y, Rannou F, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis [journal article]. Drugs Aging. 2019 April 01;36(1):101–127.
   Google Scholar
• Bodick N, Lufkin J, Willwerth C, et al. FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis. Osteoarthritis Cartilage. 2013;21:S144–S145.
   Google Scholar
• Conaghan PG, Cohen SB, Berenbaum F, et al. Brief report: a phase IIb trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. Arthritis Rheumatol. 2018;70(2):204–211.
   Google Scholar
• Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. JBJS. 2018;100(8):666–677.
   Google Scholar
• Spitzer AI, Richmond JC, Kraus VB, et al. Safety and efficacy of repeat administration of triamcinolone acetonide extended-release in osteoarthritis of the knee: A Phase 3b, Open-label Study. Rheumatol Ther. 2019 March 01;6(1):109–124.
   Google Scholar
• Langworthy MJ, Conaghan PG, Ruane JJ, et al. Efficacy of triamcinolone acetonide extended-release in participants with unilateral knee osteoarthritis: a post hoc analysis. Adv Ther. 2019 Jun;36(6):1398–1411.
   Google Scholar
• Kivitz AJ, Conaghan PG, Cinar A, et al. Rescue analgesic medication use by patients treated with triamcinolone acetonide extended-release for knee osteoarthritis pain: pooled analysis of Three Phase 2/3 randomized clinical trials. Pain Ther. 2019 May 7. doi: 10.1007/s40122-019-0125-1. [Epub ahead of print]
   Google Scholar
• Paik J, Duggan ST, Keam SJ. Triamcinolone acetonide extended-release: a review in osteoarthritis pain of the knee. Drugs. 2019 March 01;79(4):455–462.
   Google Scholar
• Davidson D, Blanc A, Filion D, et al. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem. 2005 May 27;280(21):20509–20515.
   Google Scholar
• Ellsworth JL, Berry J, Bukowski T, et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage. 2002 Apr;10(4):308–320.
   Google Scholar
• Gigout A, Guehring H, Froemel D, et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis Cartilage. 2017 Nov;25(11):1858–1867.
   Google Scholar
• Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage. 2005 Jul;13(7):623–631.
   Google Scholar
• Lohmander LS, Hellot S, Dreher D, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014 Jul;66(7):1820–1831.
   Google Scholar
• Roemer FW, Aydemir A, Lohmander S, et al. Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial. BMC Musculoskelet Disord. 2016 Jul;9(17):267.
   Google Scholar
• Eckstein F, Wirth W, Guermazi A, et al. Brief report: intraarticular sprifermin not only increases cartilage thickness, but also reduces cartilage loss: location-independent post hoc analysis using magnetic resonance imaging. Arthritis Rheumatol. 2015 Nov;67(11):2916–2922.
   Google Scholar
• Dahlberg LE, Aydemir A, Muurahainen N, et al. A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. Clin Exp Rheumatol. 2016 May-Jun;34(3):445–450.
   Google Scholar
• MC GA H, Guehring H, Aydemir A, et al. Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis. Results of the 2-year primary analysis from a 5-year randomised, placebo-controlled, phase II study. [abstract]. Arthritis Rheumatol. 2015;69(suppl):10.
   Google Scholar
• Hochberg M, Guermazi A, Guehring H, et al. OP0059 Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase ii study. Ann Rheum Dis. 2018;77(Suppl 2):80–81.
   Google Scholar
• Gühring H, Kraines J, Moreau F, et al. Cartilage thickness modification with sprifermin in knee osteoarthritis patients translates into symptomatic improvment over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II forward trial. Ann Rheum Dis. 2019;78(Suppl 2):70–71.
   Google Scholar
• Day TF, Guo X, Garrett-Beal L, et al. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005 May;8(5):739–750.
   Google Scholar
• Ge X, Ma X, Meng J, et al. Role of Wnt-5A in interleukin-1beta-induced matrix metalloproteinase expression in rabbit temporomandibular joint condylar chondrocytes. Arthritis Rheum. 2009 Sep;60(9):2714–2722.
   Google Scholar
• Zhu S, Liu H, Wu Y, et al. Wnt and Rho GTPase signaling in osteoarthritis development and intervention: implications for diagnosis and therapy. Arthritis Res Ther. 2013;15(4):217.
   Google Scholar
• Yazici YMT, Gibofsky A, Lane NE, et al. Results from a 52 week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis [abstract]. Arthritis Rheumatol. 2017;69(suppl):10.
   Google Scholar
• Oo WM, Linklater JM, Hunter DJ. Imaging in knee osteoarthritis. Curr Opin Rheumatol. 2017 Jan;29(1):86–95.
   Google Scholar
• Roemer FW, Collins J, Kwoh CK, et al. MRI-based screening for structural definition of eligibility in clinical DMOAD trials: rapid osteoarthritis MRI eligibility score (ROAMES). Osteoarthritis Cartilage. 2019 Sept 09. pii: S1063-4584(19)31192-6. doi: 10.1016/j.joca.2019.08.005. [Epub ahead of print]
   Google Scholar
• Yu SP, Hunter DJ. Intra-articular therapies for osteoarthritis. Expert Opin Pharmacother. 2016 Oct;17(15):2057–2071.
   Google Scholar
• Altman RD, Devji T, Bhandari M, et al. Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Semin Arthritis Rheum. 2016 Oct 01;46(2):151–159.
   Google Scholar
• Roman-Blas JA, Bizzi E, Largo R, et al. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin Pharmacother. 2016 Sept 01;17(13):1745–1756.
   Google Scholar
• Strand V, McIntyre LF, Beach WR, et al. Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res. 2015;8:217–228.
   Google Scholar
• Yang X, Du H, Zhai G. Progress in intra-articular drug delivery systems for osteoarthritis. Curr Drug Targets. 2014;15(9):888–900.
   Google Scholar
• Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy. Nat Rev Rheumatol. 2014 Jan;10(1):11–22.
   Google Scholar
• Maudens P, Jordan O, Allemann E. Recent advances in intra-articular drug delivery systems for osteoarthritis therapy. Drug Discov Today. 2018 May 21;23:1761–1775.
   Google Scholar
• International ORS. Osteoarthritis: a serious disease. 2016.
   Google Scholar
• Kraus VB, Simon LS, Katz JN, et al. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA’s accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthritis Cartilage. 2019 Apr;27(4):571–579.
   Google Scholar